SELLAS Life Sciences Group to Present Preclinical Data on SLS009 at AACR Conference

NEW YORK, SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, will present preclinical data on its drug candidate SLS009 (tambiciclib) at the 2026 AACR Conference on Pancreatic Cancer, held from September 25 to 28 at the Hilton San Diego Bayfront in San Diego, California.

Three posters will highlight the preclinical activity of SLS009 across patient-derived KRAS mutant organoid models of pancreatic ductal adenocarcinoma (PDAC). The studies were conducted in collaboration with the University of Wisconsin School of Medicine and Public Health.

Angelos Stergiou, SELLAS’ President and CEO, commented, "Pancreatic cancer continues to be one of the most challenging cancers to treat, and there is a significant need for new therapeutic approaches. The acceptance of these three abstracts reflects the broad scope of our preclinical work in PDAC and we are excited to share these findings with the pancreatic cancer research community."

Jeremy D. Kratz, Assistant Professor of Medicine and Principal Investigator at the University of Wisconsin-Madison, added, "These studies are designed to deepen our understanding of the mechanistic and translational rationale for CDK9 inhibition in pancreatic cancer. The presentations will explore the potential for SLS009 to create synthetic lethal interactions through rational combinations with BET- and KRAS-directed approaches, as well as its potential to exploit MYC-associated vulnerabilities."

The poster presentations will cover the following topics:

1. Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids Authors: Sawyer AG, Flannagan LE, Esguerra PN, Hossan MS, Kratz JD Poster Number: A036

2. Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma Authors: Esguerra PN, Cadarso M, Livingwell S, Hossan MD, Wong O, Kratz JD Poster Number: B127

3. Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma Authors: Cadarso M, Esguerra P, Flannagan L, Hossan MS, Kratz JD Poster Number: B043

SELLAS Life Sciences Group focuses on developing novel therapeutics for a broad range of cancer indications. Its lead product candidate, GPS, targets the WT1 protein and has the potential for use as a monotherapy and in combination with other therapies for hematologic malignancies and solid tumors. SLS009 (tambiciclib) is a potent, selective CDK9 inhibitor that shows promise as a differentiated small molecule with reduced toxicity and increased potency compared to other CDK9 inhibitors.

Stergiou concluded, "We look forward to sharing these findings and discussing their potential implications for the further development of SLS009 in solid tumors."